Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a late-stage biotechnology company developing durable, disease-targeted genetic medicines. News about 4D Molecular Therapeutics often focuses on progress in its lead programs, 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis lung disease, as well as corporate, financial and partnership developments.
For ophthalmology, company updates highlight clinical data and milestones for 4D-150 in wet age-related macular degeneration and diabetic macular edema. These include interim results from the PRISM Phase 1/2 trial, enrollment and design details for the 4FRONT Phase 3 program, and plans for global Phase 3 trials in DME. News items also cover collaborations, such as the license and development agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets.
In pulmonology, 4DMT news includes interim clinical data from the AEROW Phase 1/2 trial of 4D-710 in cystic fibrosis lung disease, describing CFTR transgene expression, lung function measures and dose selection for Phase 2. Additional coverage addresses external support, including an equity investment from the Cystic Fibrosis Foundation to help advance 4D-710.
Investors can also find announcements on equity offerings, cash runway guidance, leadership changes, board appointments, employment inducement grants and participation in healthcare and investor conferences. This news page aggregates these updates so readers can follow clinical progress, strategic partnerships, capital markets activity and governance developments related to FDMT over time.
4D Molecular Therapeutics (Nasdaq: FDMT) announced the expansion of its ophthalmology and pulmonology portfolios following positive clinical data in wet AMD and cystic fibrosis. The company filed an IND for a Phase 2 trial of 4D-150 in Diabetic Macular Edema and initiated a Phase 2 trial for wet AMD. A new preclinical candidate for Geographic Atrophy was also introduced. The interim results of the 4D-310 Fabry disease trial indicated promising cardiac endpoint improvements, with full data expected at the WORLDSymposium in February 2023. Cash guidance remains stable, funding operations through H1 2025.
4D Molecular Therapeutics (Nasdaq: FDMT) announced promising interim data from cohort 1 of their Phase 1/2 clinical trial of 4D-150 for wet AMD, showcasing a 96.7% reduction in the annualized anti-VEGF injection rate. The trial involved 5 patients who had a high pre-treatment injection rate. Notably, 80% of these patients remained injection-free for up to 10 months post-treatment, with no significant safety concerns reported. The company plans to move into randomized Phase 2 enrollment in Q1 2023, further validating the potential of their innovative gene therapy.
4D Molecular Therapeutics (Nasdaq: FDMT) has completed enrollment in all three cohorts of its Phase 1 Dose Exploration clinical trial for 4D-150 in patients with wet AMD, totaling 15 patients. All cohorts reported no dose-limiting toxicities, indicating safety. Interim clinical data from cohort 1 will be released on November 14, 2022, at 7:30 am E.T., followed by a conference call at 8:00 am E.T. The data will cover safety, efficacy, and aflibercept transgene expression. This investigational treatment aims to manage wet AMD, a condition leading to vision loss.
4D Molecular Therapeutics (FDMT) announced its third quarter 2022 financial results, reporting total revenue of $0.5 million, down from $1.4 million in Q3 2021. The net loss increased to $25.7 million from $22.2 million year-over-year. The company highlighted promising interim data from its Phase 1/2 clinical trial of 4D-710 for cystic fibrosis, showing safety and transgene expression in patients. With $239 million in cash and equivalents, FDMT expects to fund operations into the first half of 2025, emphasizing efficient cash utilization.
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim results from the Phase 1/2 trial of 4D-710 for cystic fibrosis at the NACFC. All three patients in Cohort 1 exhibited 100% successful delivery and expression of the CFTR∆R transgene in lung tissue samples. The treatment was well tolerated with no drug-related adverse events reported. Ongoing enrollment for Cohort 2 is underway, and further data is expected in 2023, highlighting the potential of 4D-710 for patients not eligible for current CFTR modulators.
4D Molecular Therapeutics (Nasdaq: FDMT) will present interim clinical data from its Phase 1/2 trial of 4D-710 at the North American Cystic Fibrosis Conference (NACFC) from November 3-5, 2022. The presentation will cover safety, tolerability, delivery, and CFTR transgene expression in cystic fibrosis patients. Following the presentation, a conference call will be hosted on November 3rd at 4:30 PM ET to discuss results. 4D-710 aims to treat cystic fibrosis via aerosol delivery, potentially benefiting a wide range of patients with various CFTR mutations.
4D Molecular Therapeutics (Nasdaq: FDMT) has appointed Noriyuki Kasahara, MD, PhD to its Board of Directors and promoted Fred Kamal, PhD to President and COO. These leadership changes aim to enhance the company's clinical development of five product candidates targeting ophthalmology, cardiology, and pulmonology. Dr. Kasahara brings over 30 years of expertise in gene therapy, while Dr. Kamal's expanded role reflects a commitment to the company's growth. The five clinical candidates are 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110, although none have FDA approval yet.
4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in two upcoming investor conferences. The first is the Jefferies Cell and Genetic Medicine Summit, featuring a corporate presentation on September 30, 2022, at 9:00 a.m. ET. The second event is Chardan’s 6th Annual Genetic Medicines Conference, where one-on-one meetings will take place on October 3, 2022. A live audio webcast of the presentation will be accessible on the company's website, with a replay available for two weeks post-event. 4DMT specializes in targeted genetic medicines and is advancing five clinical-stage products in various therapeutic areas.
4D Molecular Therapeutics (Nasdaq: FDMT) reported its second quarter 2022 financial results, showing total revenue of $0.2 million, down from $14.6 million in Q2 2021. The company maintained $261.6 million in cash and equivalents, sufficient to fund operations into the first half of 2025. Key developments include the expansion of the eligible patient population for 4D-310's Phase 1/2 trial for Fabry disease to include females. The net loss for the quarter was $28.1 million, compared to $7.6 million in the prior year.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced its participation in two major investor conferences. The company will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 8:00 a.m. ET, followed by a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PT. Investors can access a live audio webcast of these presentations on their website, with replays available for two weeks.
4DMT is focused on targeted genetic medicines using its Therapeutic Vector Evolution platform.